Business Context and Reporting Period
This Form 8-K Current Report was filed by TriSalus Life Sciences, Inc. on April 23, 2025, covering events occurring on April 20, 2025. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Westminster, Colorado.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
On April 20, 2025, George Kelly Martin resigned from his positions as a member of the Board of Directors, the Audit Committee, and the Compensation Committee, effective immediately. The Company stated that the resignation was not the result of any disagreement with the Company regarding its operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks or contingencies were disclosed in this report other than the immediate departure of a director.
Key Facts for Investors
- George Kelly Martin resigned from the Board and all committee memberships effective April 20, 2025.
- The resignation was voluntary and not related to any disagreement with the Company.
- The Company's Common Stock (TLSI) and Warrants (TLSIW) trade on the Nasdaq Global Market.
- No financial results or operational updates were included in this filing.